Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours By Ogkologos - March 2, 2026 248 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PYNNACLE study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR FDA Alters Approved Use of Two Checkpoint Inhibitors for Bladder Cancer July 26, 2018 Pink Speed Bump Reminds Drivers to Schedule Their Yearly Mammograms November 1, 2019 FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or... March 25, 2026 FDA Approves Pralsetinib for Non-Small Cell Lung Cancer with RET Gene... September 1, 2023 Load more HOT NEWS GreaterGood Is Helping UMN Fight Social Injustice with Scholarship for Underrepresented... Becoming My Own Advocate While Living With a Rare Cancer: A... 2023 ASCO Annual Meeting Research Round Up: Progress in Preventing Melanoma... Intensive Program Helps People Being Screened for Lung Cancer Quit Smoking
